Literature DB >> 20660666

Discovery of novel orally bioavailable oxaborole 6-carboxamides that demonstrate cure in a murine model of late-stage central nervous system african trypanosomiasis.

Bakela Nare1, Stephen Wring, Cyrus Bacchi, Beth Beaudet, Tana Bowling, Reto Brun, Daitao Chen, Charles Ding, Yvonne Freund, Eric Gaukel, Ali Hussain, Kurt Jarnagin, Matthew Jenks, Marcel Kaiser, Luke Mercer, Elena Mejia, Andy Noe, Matt Orr, Robin Parham, Jacob Plattner, Ryan Randolph, Donna Rattendi, Cindy Rewerts, Jessica Sligar, Nigel Yarlett, Robert Don, Robert Jacobs.   

Abstract

We report the discovery of novel boron-containing molecules, exemplified by N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-2-trifluoromethylbenzamide (AN3520) and 4-fluoro-N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-2-trifluoromethylbenzamide (SCYX-6759), as potent compounds against Trypanosoma brucei in vitro, including the two subspecies responsible for human disease T. b. rhodesiense and T. b. gambiense. These oxaborole carboxamides cured stage 1 (hemolymphatic) trypanosomiasis infection in mice when administered orally at 2.5 to 10 mg/kg of body weight for 4 consecutive days. In stage 2 disease (central nervous system [CNS] involvement), mice infected with T. b. brucei were cured when AN3520 or SCYX-6759 were administered intraperitoneally or orally (50 mg/kg) twice daily for 7 days. Oxaborole-treated animals did not exhibit gross signs of compound-related acute or subchronic toxicity. Metabolism and pharmacokinetic studies in several species, including nonhuman primates, demonstrate that both SCYX-6759 and AN3520 are low-clearance compounds. Both compounds were well absorbed following oral dosing in multiple species and also demonstrated the ability to cross the blood-brain barrier with no evidence of interaction with the P-glycoprotein transporter. Overall, SCYX-6759 demonstrated superior pharmacokinetics, and this was reflected in better efficacy against stage 2 disease in the mouse model. On the whole, oxaboroles demonstrate potent activity against all T. brucei subspecies, excellent physicochemical profiles, in vitro metabolic stability, a low potential for CYP450 inhibition, a lack of active efflux by the P-glycoprotein transporter, and high permeability. These properties strongly suggest that these novel chemical entities are suitable leads for the development of new and effective orally administered treatments for human African trypanosomiasis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20660666      PMCID: PMC2944573          DOI: 10.1128/AAC.00498-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  42 in total

Review 1.  Human African trypanosomiasis of the CNS: current issues and challenges.

Authors:  Peter G E Kennedy
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

2.  Human African trypanosomiasis.

Authors:  Reto Brun; Johannes Blum; Francois Chappuis; Christian Burri
Journal:  Lancet       Date:  2009-10-14       Impact factor: 79.321

3.  Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers.

Authors:  H Hirumi; K Hirumi
Journal:  J Parasitol       Date:  1989-12       Impact factor: 1.276

Review 4.  Human drug metabolism in vitro.

Authors:  P H Beaune; F P Guengerich
Journal:  Pharmacol Ther       Date:  1988       Impact factor: 12.310

5.  Cultivation of parasites in vitro.

Authors:  W Trager
Journal:  Am J Trop Med Hyg       Date:  1978-03       Impact factor: 2.345

6.  Effects of the ornithine decarboxylase inhibitors DL-alpha-difluoromethylornithine and alpha-monofluoromethyldehydroornithine methyl ester alone and in combination with suramin against Trypanosoma brucei brucei central nervous system models.

Authors:  C J Bacchi; H C Nathan; A B Clarkson; E J Bienen; A J Bitonti; P P McCann; A Sjoerdsma
Journal:  Am J Trop Med Hyg       Date:  1987-01       Impact factor: 2.345

7.  Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding.

Authors:  Kelly M Mahar Doan; Stephen A Wring; Larry J Shampine; Kelly H Jordan; James P Bishop; John Kratz; Eric Yang; Cosette J Serabjit-Singh; Kimberly K Adkison; Joseph W Polli
Journal:  Pharmacology       Date:  2004-10       Impact factor: 2.547

8.  Relapsed parasitaemia following chemotherapy of chronic T. brucei infections in mice and its relation to cerebral trypanosomes.

Authors:  F W Jennings; G D Gray
Journal:  Contrib Microbiol Immunol       Date:  1983

9.  In vitro absorption and secretory quotients: practical criteria derived from a study of 331 compounds to assess for the impact of P-glycoprotein-mediated efflux on drug candidates.

Authors:  Victoria E Thiel-Demby; Timothy K Tippin; Joan E Humphreys; Cosette J Serabjit-Singh; Joseph W Polli
Journal:  J Pharm Sci       Date:  2004-10       Impact factor: 3.534

10.  Cultivation in a semi-defined medium of animal infective forms of Trypanosoma brucei, T. equiperdum, T. evansi, T. rhodesiense and T. gambiense.

Authors:  T Baltz; D Baltz; C Giroud; J Crockett
Journal:  EMBO J       Date:  1985-05       Impact factor: 11.598

View more
  39 in total

1.  In Vitro and in Vivo Activity of Multitarget Inhibitors against Trypanosoma brucei.

Authors:  Gyongseon Yang; Wei Zhu; Yang Wang; Guozhong Huang; Soo Young Byun; Gahee Choi; Kai Li; Zhuoli Huang; Roberto Docampo; Eric Oldfield; Joo Hwan No
Journal:  ACS Infect Dis       Date:  2015-07-31       Impact factor: 5.084

Review 2.  Progress and challenges in aminoacyl-tRNA synthetase-based therapeutics.

Authors:  Christopher S Francklyn; Patrick Mullen
Journal:  J Biol Chem       Date:  2019-01-22       Impact factor: 5.157

3.  Phosphodiesterase inhibitors as a new generation of antiprotozoan drugs: exploiting the benefit of enzymes that are highly conserved between host and parasite.

Authors:  Thomas Seebeck; Geert Jan Sterk; Hengming Ke
Journal:  Future Med Chem       Date:  2011-08       Impact factor: 3.808

4.  Topical Treatment for Cutaneous Leishmaniasis: Dermato-Pharmacokinetic Lead Optimization of Benzoxaboroles.

Authors:  Katrien Van Bocxlaer; Eric Gaukel; Deirdre Hauser; Seong Hee Park; Sara Schock; Vanessa Yardley; Ryan Randolph; Jacob J Plattner; Tejal Merchant; Simon L Croft; Robert T Jacobs; Stephen A Wring
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

Review 5.  Advances in Drug Discovery and Development for Pediatric Tuberculosis.

Authors:  Daniel Hoagland; Ying Zhao; Richard E Lee
Journal:  Mini Rev Med Chem       Date:  2016       Impact factor: 3.862

6.  Phenotypic Screens Reveal Posaconazole as a Rapidly Acting Amebicidal Combination Partner for Treatment of Primary Amoebic Meningoencephalitis.

Authors:  Beatrice L Colon; Christopher A Rice; R Kiplin Guy; Dennis E Kyle
Journal:  J Infect Dis       Date:  2019-03-15       Impact factor: 5.226

7.  Application of a resazurin-based high-throughput screening assay for the identification and progression of new treatments for human African trypanosomiasis.

Authors:  Tana Bowling; Luke Mercer; Robert Don; Robert Jacobs; Bakela Nare
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-03-03       Impact factor: 4.077

8.  SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis.

Authors:  Robert T Jacobs; Bakela Nare; Stephen A Wring; Matthew D Orr; Daitao Chen; Jessica M Sligar; Matthew X Jenks; Robert A Noe; Tana S Bowling; Luke T Mercer; Cindy Rewerts; Eric Gaukel; Jennifer Owens; Robin Parham; Ryan Randolph; Beth Beaudet; Cyrus J Bacchi; Nigel Yarlett; Jacob J Plattner; Yvonne Freund; Charles Ding; Tsutomu Akama; Y-K Zhang; Reto Brun; Marcel Kaiser; Ivan Scandale; Robert Don
Journal:  PLoS Negl Trop Dis       Date:  2011-06-28

9.  Clinical and veterinary trypanocidal benzoxaboroles target CPSF3.

Authors:  Richard J Wall; Eva Rico; Iva Lukac; Fabio Zuccotto; Sara Elg; Ian H Gilbert; Yvonne Freund; M R K Alley; Mark C Field; Susan Wyllie; David Horn
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-05       Impact factor: 11.205

10.  Identification of compounds with anti-proliferative activity against Trypanosoma brucei brucei strain 427 by a whole cell viability based HTS campaign.

Authors:  Melissa L Sykes; Jonathan B Baell; Marcel Kaiser; Eric Chatelain; Sarah R Moawad; Danny Ganame; Jean-Robert Ioset; Vicky M Avery
Journal:  PLoS Negl Trop Dis       Date:  2012-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.